AbbVie (ABBV) Tax Rate (2012 - 2026)
AbbVie's (ABBV) quarterly Tax Rate came in at 15.47% in Q2 2026, down 2397.0% year-over-year from 0.67% in Q2 2025, and down 52.99% quarter-over-quarter from 32.92% in Q1 2026.
Analysis
AbbVie (ABBV) Tax Rate (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Tax Rate for 15 consecutive years, with 15.47% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Tax Rate fell 2397.0% year-over-year to 15.47% in Q2 2026; TTM through Jun 2026 was 27.39%, a 5185.0% increase from a year earlier, with the FY2025 full-year figure at 35.83%, up 5117.0% from the prior year.
- Tax Rate was 15.47% for Q2 2026 at AbbVie, down from 32.92% in the prior quarter.
- Over five years, Tax Rate peaked at 120.42% in Q1 2023 and troughed at 8.81% in Q3 2023.
- A 5-year average of 35.47% and a median of 23.67% in 2024 frame the typical range for Tax Rate.
- Across the five-year window, Tax Rate soared 11158 bps in 2023 and slumped 9860 bps in 2024, its largest moves.
- Over 5 years, Tax Rate stood at 16.63% in 2022, then surged by 93 bps to 32.01% in 2023, then surged by 209 bps to 98.99% in 2024, then plunged by 68 bps to 31.97% in 2025, then sank by 52 bps to 15.47% in 2026.
- The last three Tax Rate figures came in at 15.47% (Q2 2026), 32.92% (Q1 2026), and 31.97% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 17.98% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 15.47% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -95.75% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -23.71% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 62.33% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -31.96% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 22.08% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 10.65% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 10.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.47% |
| Mar 31, 2026 | 32.92% |
| Dec 31, 2025 | 31.97% |
| Sep 30, 2025 | 73.67% |
| Jun 30, 2025 | 39.45% |
| Mar 31, 2025 | 22.40% |
| Dec 31, 2024 | 98.99% |
| Sep 30, 2024 | 24.95% |
| Jun 30, 2024 | 36.02% |
| Mar 31, 2024 | 21.82% |
| Dec 31, 2023 | 32.01% |
| Sep 30, 2023 | 8.81% |
| Jun 30, 2023 | 22.34% |
| Mar 31, 2023 | 120.42% |
| Dec 31, 2022 | 16.63% |
| Sep 30, 2022 | 10.18% |
| Jun 30, 2022 | 21.56% |
| Mar 31, 2022 | 8.85% |
| Dec 31, 2021 | 5.29% |
| Sep 30, 2021 | 13.77% |